The ECM can be degraded, and a distortion of the balance between ECM synthesis and turnover may result in an abnormal ECM accumulation in the mesangium in diabetic nephropathy. Plasminogen activator inhibitor-1 (PAI-1) is a component of the ECM and plays an important role in regulating blood coagulation and ECM accumulation. High media glucose concentration increases PAI-1 secretion (10) or activates the PAI-1 gene promoter in mesangial cells (11) . However, the effects of glycated albumin on mesangial cell PAI-1 gene expression are unknown.
PAI-1 gene transcription is activated by TGF-␤ (9, 35, 39) . TGF-␤ signals through sequential activation of two cell-surface receptor serine-threonine kinases, which phosphorylate Smad2 and/or Smad3 (19, 22, 25, 40, 44) . The phosphorylated Smads form heteromeric complexes with Smad4, which then translocate to the nucleus. In the nucleus, the Smad3-Smad4 complex can activate transcription through direct binding to DNA (9, 43) .
Two different consensus sequences for Smad binding, such as GTCTAGAC (Smad-binding element) (43) and AG(C/ A)CAGACAC (CAGA box) (9), have been described. Both sequences contain the core motif AGAC, which represents the optimal binding sequence for Smad3 and Smad4 (33, 43) . CAGA boxes appear to be necessary and sufficient to mediate TGF-␤ transcriptional effects (9) , and human PAI-1 promoter contains three CAGA boxes (9, 12, 36) .
We raised the possibility that glycated albumin influences PAI-1 gene expression in human mesangial cells (HMC) and that glycated albumin-induced PAI-1 expression is mediated by the TGF-␤/Smad signaling pathway. To address this question, we examined the effects of glycated albumin on TGF-␤ 1 and PAI-1 mRNA expression, PAI-1 promoter activity, and DNA binding activity of Smad proteins in HMC.
(St. Louis, MO). Other reagents were from sources as previously reported (14, 34) .
Culture of HMC and preparation of glycated albumin. HMC were obtained from adult nephrectomy specimens, as previously described (14, 15) . The culture medium was made of DMEM supplemented with 20% fetal calf serum, 200 mM L-glutamine, and antibiotics. For the present experiments, cells from between passages 5 and 7 were used.
Glycated BSA (Gly-BSA) was prepared by incubating 10 mg/ml BSA (fraction V) in PBS containing protease inhibitors and antibiotics for 7 days at 37°C in the presence of 0.3 mol/l D-glucose. Native BSA was processed under the same conditions in the absence of glucose. At the end of the incubation period, the solutions were dialyzed against PBS at 4°C for 24 h to remove unincorporated sugars and/or antibiotics and then sterile filtered. The extent of glycation of Gly-BSA, as measured by m-aminophenyl-boronate affinity chromatography (38) , reached 76%. We measured bacterial endotoxin in BSA preparations using the Limulus amebocyte lysate test gel-clot method (1) . No endotoxin was detected.
Experimental conditions. HMC were grown to confluency. The cells were synchronized to quiescence in serum-free DMEM containing 5 g/ml insulin-transferrin-selenite for 48 h. After synchronization, experiments were performed by the addition of 200 -1,000 g/ml of Gly-BSA or BSA to the HMC for 12-72 h at 37°C. In given experiments, simultaneous control monolayers were treated with DMEM alone. In nondiabetic individuals, ϳ1% of serum albumin is in the glycated form, which is equivalent to concentrations of 300 -400 g/ml of glycated albumin (46) . Plasma Amadori albumin levels in patients with diabetic nephropathy are 2.5-fold higher than in healthy control subjects (31) .
Northern blot analysis. Isolated RNA samples were transferred onto nylon filters. The blotted membranes were incubated with the specific 32 P-labeled cDNA probes for human TGF-␤1, PAI-1, and ␤-actin as we previously described (14, 34) . The filters were dried and exposed at Ϫ70°C using Agfa film (Agfa-Gevaert, Hortsel, Belgium). The mRNA levels for TGF-␤ 1 and PAI-1 were expressed as a ratio of the optical density units for TGF-␤ 1 or PAI-1 to ␤-actin.
Western blot analysis. Cell lysates or nuclear extracts were electrophoretically resolved using a 10% polyacrylamide gel in an SDS buffer and then transferred onto nitrocellulose membranes as previously described (16) . The blots were incubated in blocking solution for 1 h and incubated with rabbit anti-Smad3 and anti-Smad2/3 or mononclonal antibody against human PAI-1. Bound primary antibody was visualized after incubation with horseradish peroxidase-conjugated secondary antibody using an enhanced chemiluminescence system kit (Amersham, Arlington Heights, IL). To assess the equality of protein loading, the membrane was reprobed with anti-actin or anti-CREB-1 antibody (1:1,000 dilution).
Plasmid constructs. PAI-1 reporter vectors (740PAI-1-LUC) were generated using pGL3-basic plasmid (Promega) containing the firefly luciferase coding sequence. The oligonucleotides containing the sequence from Ϫ740 to ϩ44 of the human PAI-1 promoter were prepared by PCR from genomic DNA and inserted between BgIII and Sac1 cloning sites of pGL3-basic vector. The sequences of the oligonucleotide cloned were 5Ј-TTG-AGC-TGC-CCA-GAC-AAG-GTT-GTT-GAC-3Ј and its complementary strand 5Ј-CGA-GAT-CTG-TCT-TCT-TGA-CAG-CGC-TCT-TGG-3Ј (24) .
Preparation of CAGA, mutant CAGA, and phosphorothioate CAGA oligonucleotides. The sequence of the double-strand CAGA oligonucleotides was 5Ј-TCG-AGA-GCC-AGA-CAA-AAA-GCC-AGA-CAT-TTA-GCC-AGA-CAC-3Ј and its complementary strand (9) . The sequence of the mutant CAGA oligonucleotides was 5Ј-TCG-AGA-GCT-ACA-TAA-AAA-GCT-ACA-TAT-TTA-GCT-ACA-TAC-3Ј and its complementary strand (9) .
Oligonucleotides with modified phosphodiester bonds, such as phosphorothioate, are relatively resistant to nucleases and have been used as antisense agents (20) . In this respect, CAGA antisense analog was prepared by attaching phosphorothioate to each end of CAGA oligonucleotides.
Transfection and luciferase assays. Cells were grown in six-well plates to 80% confluence. The cells were transfected with 2 g of DNA (1.5 g of PGL3-PAI-1 construct and 0.5 g of pCMV-␤gal) mixed with Lipofectamine according to the manufacturer's instructions. After 6 h of transfection, cells were serum starved for 8 h before incubation with BSA or Gly-BSA for 24 h. Then, cells were lysed on ice in 100 mM KH2PO4, pH 7.9, and 0.5% Triton X-100 and centrifuged. Luciferase and ␤-galactosidase assays were performed with reagents from Promega. Luciferase activity was normalized to ␤-galactosidase activity.
Preparation of nuclear extracts. Nuclear extracts were prepared as previously described by Schreiber et al. (32) . Briefly, the cells were washed with Tris-buffered saline (TBS), centrifuged, and resuspended in 400 l cold buffer A [(in mM) 10 HEPES, pH 7.9, 10 KCl, 0.1 EDTA, 0.1 EGTA, 1 dithiothreitol, 0.5 PMSF]. After a 15-min incubation on ice, 25 l of a 10% solution of nonionic detergent Nonidet P-40 were added. After centrifugation, the nuclear pellet was resuspended in 50 l ice-cold buffer B (20 HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) and the tube was rocked at 4°C for 15 min on a shaking platform. The nuclear extracts were centrifuged, and the supernatant was frozen in aliquots. Protein content was measured using bicinchoninic acid with BSA as a standard. EMSA. The human PAI-1 promoter construct and CAGA oligonucleotides described above were end-labeled with [␥-32 P]ATP using the T4 polynucleotide kinase. Five micrograms of nuclear extracts were incubated for 30 min at 4°C with 40,000 cpm of 32 P-labeled probes in 10 mM HEPES, pH 7.9, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, and 1 g of poly(deoxyinosin-deoxycytosin). The DNA-protein complexes were separated on a 5% polyacrylamide gel in 0.5ϫ TBE buffer and visualized by autoradiography.
For competition and supershift assays, nuclear extracts were preincubated with a 100-fold molar excess of unlabeled CAGA oligonucleotides or 10 l of mouse monoclonal anti-Smad3 or anti-Smad4 for 30 min or overnight before addition of the labeled probe.
Statistics. Results were expressed as means Ϯ SD of three separate experiments. Results were analyzed by the two-way ANOVA for three groups or by Wilcoxon's rank sum test between two groups. A P value of Ͻ0.05 was considered significant.
RESULTS
Gly-BSA stimulates TGF-␤ 1 mRNA expression. Twelve to twenty-four hours after incubation with HMC, Gly-BSA at a concentration of 200 g/ml significantly increased TGF-␤ 1 mRNA synthesis to 1.8 times that in the BSA-treated control cells (Fig. 1) .
Gly-BSA increases PAI-1 expression and PAI-1 gene promoter activity.
Gly-BSA at a concentration of 200 g/ml significantly increased PAI-1 mRNA transcripts to 3.2 times the levels in the BSA-treated cells at 24 h, but this effect disappeared at 48 and 72 h (Fig. 2) . When a dose-response of Gly-BSA was tested at 24 h, no significant difference was observed between 200 and 1,000 g/ml Gly-BSA in PAI-1 mRNA expression (data not shown).
Incubation of HMC with 200 g/ml of Gly-BSA for 24 h increased PAI-1 protein expression 1.5 times the control levels, as assessed by Western blotting (Fig. 3) .
In cells transfected with the 740PAI-1-LUC construct, containing the sequence from Ϫ740 to ϩ44 of the human PAI-1 promoter in front of the luciferase reporter gene, Gly-BSA treatment for 48 h increased luciferase activity 2.3 times compared with that in BSA-treated cells (Fig. 4) .
Gly-BSA increases nuclear Smad2/3 and Smad3 expression in HMC. Because activated Smads are translocated into the nucleus, we measured the expression of Smads using nuclear extracts by Western blotting. Incubation of HMC with 200 g/ml of Gly-BSA for 24 h increased Smad2/3 or Smad3 expression 1.6 -2.5 times the control levels in the nuclei (Fig.  5) . When we tested a dose-response of Gly-BSA at 24 h, no significant difference was found between 200 and 1,000 g/ml Gly-BSA in nuclear Smad3 expression (data not shown).
Anti-TGF-␤ attenuates Gly-BSA-induced increases in nuclear Smad3 expression. When cells were incubated with pan-specific anti-TGF-␤ antibody (25 g/ml) along with Gly-BSA for 24 h, the expected increase in Smad3 expression was significantly reduced. However, the same concentration of control rabbit IgG had no effect on the Gly-BSA-induced increase in Smad3 levels (Fig. 6) . 
Gly-BSA increases the DNA/protein-binding complexes.
An EMSA was performed using a Ϫ740 to ϩ44 PAI-1 promoter construct or an oligonucleotide containing three CAGA boxes as a probe. Nuclear extracts were prepared from HMC exposed to 200 g/ml of BSA or Gly-BSA for 24 h. DNA/protein complexes were identified, and their intensity significantly increased in Gly-BSA-treated cells vs.BSA-treated cells (Fig.  7A, top, lanes 1 and 2) .
Smad3 is present in the DNA/protein complexes and binds to the CAGA box in the PAI-1 promoter. To demonstrate the presence of Smad3 or Smad4 in the DNA/protein complexes, monoclonal antibody against Smad3 or Smad4 was incubated with nuclear extracts from Gly-BSA-treated cells before addition of the radiolabeled probe. Addition of anti-Smad3 resulted in a slower migrating complex, whereas formation of DNA/ protein complex was completely inhibited [Fig. 7, B (lane 3) and C (lane 2)]. With anti-Smad4, DNA/protein complex formation was also inhibited, although no supershifted complex was detected (Fig. 7B, lane 4) . As expected, normal mouse IgG did not affect formation of these complexes (Fig.  7C, lane 3) .
To prove that the Smad3-binding sequences within the PAI-1 promoter are CAGA boxes, CAGA oligonucleotides were used as cold competitors in the EMSA. When nuclear extracts were preincubated with 100-fold molar excess of unlabeled CAGA oligonucleotides before addition of radiolabeled probe, the complex formation was prevented (Fig. 7B,  lane 2) . These results suggest that Gly-BSA increases the binding activity of Smad3 to the CAGA box within the PAI-1 promoter. Gly-BSA increases PAI-1 transcription mediated by the CAGA sequences. To examine whether Gly-BSA-induced PAI-1 transcription is mediated through Smad-binding CAGA sequences, phosphorothioate CAGA oligonucleotides and mutant CAGA oligonucleotides were transfected into HMC. Transfection of cells using 32 P-labeled phosphorothioate CAGA oligonucleotides resulted in strong radioactivity, confirming their successful transfection. On Gly-BSA treatment, phosphorothioate CAGA oligonucleotide-transfected cells exhibited significantly reduced PAI-1 mRNA expression compared with nontransfected cells or mutant CAGA oligonucleotide-transfected cells (Fig. 8) . Luciferase activity on Gly-BSA treatment was significantly decreased in cells cotransfected with phosphorothioate CAGA oligonucleotide and 740PAI-1-LUC compared with those transfected with 740PAI-1-LUC alone (Fig. 9) .
DISCUSSION
This study demonstrates, to the best of our knowledge for the first time, that Gly-BSA increases PAI-1 mRNA expression, PAI-1 promoter activity, and DNA-binding activity of Smad3 in HMC. Furthermore, it shows that the Gly-BSAinduced PAI-1 gene upregulation is mediated through Smad3-binding CAGA sequences in the PAI-1 promoter.
We found that treatment of mesangial cells with Gly-BSA at a concentration of 200 g/ml increased steady-state PAI-1 mRNA levels at 24 h. We also observed that Gly-BSA increased transiently transfected PAI-1 promoter activity compared with that in BSA-treated cells. These findings are similar to results with mesangial cells incubated with high ambient glucose (11) . However, we could not observe a dose-response effect in PAI-1 mRNA and Smad3 expression between 200 and 1,000 g/ml Gly-BSA, suggesting that concentrations of glycated albumin to activate the TGF-␤/signaling pathway in cultured mesangial cells might be lower than those found in clinical specimens. Ziyadeh et al. (46) also observed a minimal or negligible difference between 200 and 600 g/ml glycated albumin in inducing fibronectin and TGF-␤ 1 mRNA expression.
In agreement with the report of Ziyadeh et al. (46), we found that Gly-BSA increased TGF-␤ 1 mRNA expression. Increased glomerular TGF-␤ 1 , which can be induced by either elevated glucose or glycated albumin in kidneys of diabetic animals (42) , stimulates the production of fibronectin and type IV collagen (46) . Similarly, Gly-BSA-induced TGF-␤ 1 upregulation observed in this study could increase mesangial PAI-1 overproduction, which can be linked to the development of mesangial matrix accumulation.
In the present study, incubation of Gly-BSA with HMC increased nuclear Smad2 and Smad3 protein levels compared with those in BSA-treated cells. Although high-glucose-induced phosphorylated Smad2 expression was demonstrated in the nuclei of mesangial cells by immunohistochemistry (18) , no study has shown that glycated albumin can induce enhanced nuclear Smad2 and Smad3 expression in mesangial cells. Our results with increased nuclear Smad2 and Smad3 expression by Gly-BSA suggest that glycated albumin can activate Smad signaling in mesangial cells with translocation of Smad com- plexes into nuclei. Furthermore, anti-TGF-␤ significantly attenuated the Gly-BSA-induced increases in nuclear Smad3 expression in this study, suggesting an intermediate role for TGF-␤ in the effects of the Gly-BSA-induced Smad pathway.
Our EMSA results demonstrate that Gly-BSA significantly increased the intensity of DNA/protein (binding) complexes within the Ϫ740 to ϩ44 region of the PAI-1 promoter compared with BSA. We also found that the PAI-1 promoter-or CAGA sequence-binding protein was Smad3 by antibody supershift, confirming the report of Dennler et al. (9) . Furthermore, we observed that formation of the DNA/protein complex was also inhibited with anti-Smad4, suggesting that Smad4 can also bind to the CAGA boxes. However, a supershifted complex was not detected with anti-Smad4, possibly because the amounts of Smad4 bound to the complex are too small to be detected.
Smad2 cannot bind directly to DNA compared with Smad3 (23, 41) . Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice (45) . In cultured mesangial cells, Smad3 overexpression increases fibronectin promoter activity (13) , and Smad3 has been found to be involved in TGF-␤-induced stimulation of the ␣ 2 (I) collagen (26, 27) . Although Smad4 is essential for TGF-␤-induced ␣ 1 (I) collagen expression in mesangial cells, TGF-␤-induced fibronectin expression and sustained TGF-␤-induced PAI-1 expression are independent of Smad4 (37) . These reports together with our observations showing Gly-BSA-induced increased Smad3/DNA interactions suggest that Smad3 plays a key role in intracellular Smad signaling and ECM accumulation.
In our study, transfection of phosphorothioate CAGA oligonucleotides, a CAGA antisense analog, inhibited Gly-BSAinduced PAI-1 mRNA expression. Cotransfection of the phosphorothioate CAGA oligonucleotide with the PAI-1 promoter construct also blocked Gly-BSA-induced luciferase activity. These results suggest that CAGA boxes in the PAI-1 promoter could mediate Gly-BSA-induced PAI-1 promoter activation and PAI-1 gene transcription in HMC.
In the present study, the increase in Smad/DNA binding could explain the increased PAI-1 promoter activity induced by Gly-BSA. CAGA boxes themselves might be sufficient to mediate TGF-␤ transcriptional effects (9), although Smads must cooperate with other transcription factors to effect the transcription of a target gene (8, 21) .
Increased levels of glycated albumin seem to be related to multiple diabetic complications (31) . Upregulation of PAI-1 gene expression by glycated albumin may be relevant to diabetic nephropathy. Not only high glucose (10, 11) but also low-density lipoprotein (34) , mediators of diabetic nephropathy, stimulate expression of PAI-1 in mesangial cells. PAI-1 has been implicated in renal disease as being a mediator of ECM accumulation (28) and as a feedback mechanism to limit vascular fibrinolysis (17, 29) . Our results describing the Gly-BSA-induced transcriptional activation of PAI-1 suggest that increased circulating glycated albumin levels in diabetic patients could lead to a mesangial ECM accumulation and to eventual renal fibrosis partly linked to impaired matrix degradation.
In summary, our results show that Gly-BSA increases DNA binding activity of Smad3 and that it stimulates PAI-1 transcription through Smad-binding CAGA boxes in the PAI-1 promoter in HMC. Thus progression of diabetic nephropathy may be promoted by PAI-1 upregulation mediated by the glycated albumin-induced Smad/DNA interactions.
